XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
US Stock MarketDetailed Quotes
PCRX Pacira BioSciences
- 25.440
- -1.090-4.11%
Close Feb 14 16:00 ET
- 25.440
- 0.0000.00%
Post 16:01 ET
1.17BMarket Cap-12.85P/E (TTM)
27.000High25.440Low615.94KVolume26.570Open26.530Pre Close15.94MTurnover1.42%Turnover Ratio28.58P/E (Static)46.17MShares31.67052wk High1.57P/B1.10BFloat Cap11.16452wk Low--Dividend TTM43.32MShs Float121.950Historical High--Div YieldTTM5.88%Amplitude6.160Historical Low25.875Avg Price1Lot Size
About Pacira BioSciences Company
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Company Profile
SymbolPCRX
Company NamePacira BioSciences
Listing DateFeb 3, 2011
Issue Price7.00
Founded2006
CEOMr. Frank D. Lee
MarketNASDAQ
Employees712
Fiscal Year Ends12-31
Address5401 West Kennedy Boulevard,Suite 890
CityTampa
ProvinceFlorida
CountryUnited States of America
Zip Code33609
Phone1-813-553-6680
Websitehttp://www.pacira.com
Company Executives
- Name
- Position
- Salary
- Frank D. Lee
- Director and Chief Executive Officer
- --
- Brendan P. Teehan
- Chief Commercial Officer
- --
- Shawn M. Cross
- Chief Financial Officer
- --
- Krys Corbett
- Chief Business Officer
- --
- Jonathan Slonin
- Chief Medical Officer
- 1.59M
- Kristen Marie Williams
- Chief Administrative Officer and Secretary
- 1.60M
- Lauren Riker
- Principal Accounting Officer and Senior Vice President, Finance
- --
- Daryl Gaugler
- Executive Vice President, Commercial Operations
- 1.53M
- Laura A. Brege
- Chairman of the Board
- 364.01K
- Governor Christopher J. Christie
- Independent Director
- 325.01K
- Alethia Young
- Independent Director
- 427.86K
- Michael J. Yang
- Independent Director
- 427.16K
- Dr. Marcelo Bigal, M.D.,PhD
- Independent Director
- 426.45K
- Abraham N. Ceesay, M.B.A.
- Independent Director
- 427.16K
- Dr. Mark A. Kronenfeld, M.D.
- Independent Director
- 373.01K
- Dr. Mark I. Froin, M.D.
- Independent Director
- 349.01K
Trending Stocks
Discussing
FOMC leaves rates unchanged, how will you adjust your portfolio?
FOMC left the target Federal Funds rate unchanged at at target of 4.25%-4.5%, how will you adjust your portfolio?
Moo Live
Jan 30 03:25
FOMC Press Conference, January 29, 2025